← Eichor
Condition: Erbb2 Gene Amplification Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Erbb2 Gene Amplification

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Phase 1 · 6 location(s) · Cogent Biosciences, Inc. · NCT07361562Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or M
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT06749860A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Phase 2 · 221 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04879329Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-posi
Phase 3 · 185 location(s) · Jazz Pharmaceuticals · NCT06282575Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Phase 1/Phase 2 · 42 location(s) · ORIC Pharmaceuticals · NCT05315700DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adul
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05786716Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Ot
Phase 1/Phase 2 · 33 location(s) · Novartis Pharmaceuticals · NCT06726148Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Avenzo Therapeutics, Inc. · NCT05867251Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and
Phase 1/Phase 2 · 14 location(s) · Novartis Pharmaceuticals · NCT07288359Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06813456
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.